



DIAGNOS
Your Knowledge Partner

PRESS RELEASE

OCTQB : DGNOD
TSXV : ADK
SOURCE : DIAGNOS Inc.

2019.06.04

DIAGNOS Announces the Appointment of Mr. Riadh Kobbi as Vice President Business Intelligence

Brossard, Quebec, Canada – June 04th, 2019 - Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (OTCQB: DGNOD), a leader in early detection of critical health issues through the use of Artificial Intelligence (*AI*), announces today the appointment of Riadh Kobbi as Vice President Business Intelligence.

Riadh has more than 20 years of international experience in the statistics field applied to computer software, having occupied executive roles in companies located in France, Turkey, Morocco and Cyprus. Riadh is one the first graduates of the master program in Business Intelligence at HEC Montreal. “After more than a decade at DIAGNOS in the development of expertise in predictive analytics and modeling, I am extremely proud to accept this new role and take on this new challenge along with my teammates dedicated to the success of DIAGNOS”, said Riadh Kobbi.

“We are very proud to have Riadh at DIAGNOS. He has been with our team for 14 years and has always been a creative and a positive employee, even throughout difficult times. We are looking forward to Riadh’s new position and are confident he will lead our technical team towards a successful future”, said André Larente, CEO of DIAGNOS.

About DIAGNOS

DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America, is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.

Additional information is available at www.diagnos.com and www.sedar.com

For further information, please contact:

Mr. André Larente, President
DIAGNOS Inc
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS

disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

– 30 –